Drug Profile
Research programme: recombinant human biglycan - Tivorsan
Alternative Names: Biglycan; rh-BGN; TVN-102Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Brown University
- Developer Tivorsan Pharmaceuticals
- Class Proteoglycans
- Mechanism of Action Utrophin activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Duchenne muscular dystrophy; Muscular dystrophies
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Muscular dystrophies in USA (Parenteral)